InspireMD (NSPR) 10-K 7 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 04, 2022	Jun. 30, 2021
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-35731
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	0001433607
Entity Tax Identification Number	26-2123838
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4 Menorat Hamaor St.
Entity Address, City or Town	Tel Aviv
Entity Address, Country	IL
Entity Address, Postal Zip Code	6744832
City Area Code	(888)
Local Phone Number	776-6804
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 38,913,674
Entity Common Stock, Shares Outstanding		8,322,439
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Auditor Firm ID	1309
Auditor Name	Kesselman&Kesselman
Auditor Location	Tel-Aviv, Israel
Common Stock [Member]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NSPR
Security Exchange Name	NASDAQ
Series B Warrants [Member]
Title of 12(b) Security	Series B Warrants, exercisable for one share of Common Stock
Trading Symbol	NSPRZ
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents		$ 12,004	$ 12,645
Short-term bank deposits		22,036
Accounts receivable:
Trade, net		1,224	476
Other		165	146
Prepaid expenses		522	334
Inventory		1,143	1,415
Receivable for sale of Shares			323
TOTAL CURRENT ASSETS		37,094	15,339
NON-CURRENT ASSETS:
Property, plant and equipment, net		632	448
Operating lease right of use assets		1,081	1,265
Fund in respect of employee rights upon retirement		905	725
TOTAL NON-CURRENT ASSETS		2,618	2,438
TOTAL ASSETS		39,712	17,777
Accounts payable and accruals:
Trade		893	236
Other		3,454	3,469
TOTAL CURRENT LIABILITIES		4,347	3,705
LONG-TERM LIABILITIES:
Operating lease liabilities		781	999
Liability for employee rights upon retirement		1,052	910
TOTAL LONG-TERM LIABILITIES		1,833	1,909
COMMITMENTS AND CONTINGENT LIABILITIES (Note 6)
TOTAL LIABILITIES		6,180	5,614
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2021 and 2020; 8,296,256 and 3,284,322 shares issued and outstanding at December 31, 2021 and 2020, respectively		1		[1]
Additional paid-in capital		216,625	180,339
Accumulated deficit		(183,094)	(168,176)
Total equity		33,532	12,163
Total liabilities and equity		39,712	17,777
Series B Preferred Stock [Member]
EQUITY:
Preferred stock, value				[1]
Series C Preferred Stock [Member]
EQUITY:
Preferred stock, value	[1]
[1]	Represents an amount less than $1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	8,296,256	3,284,322
Common stock, shares outstanding	8,296,256	3,284,322
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	17,303
Preferred stock, shares outstanding	0	17,303
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares issued	1,718	2,343
Preferred stock, shares outstanding	1,718	2,343

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
REVENUES (2020 - net of settlement payment of $580, see note 6 a)	$ 4,495	$ 2,485
COST OF REVENUES	3,741	2,402
GROSS PROFIT	754	83
OPERATING EXPENSES:
Research and development	5,158	2,233
Selling and marketing	2,907	2,103
General and administrative	7,405	6,127
Total operating expenses	15,470	10,463
LOSS FROM OPERATIONS	(14,716)	(10,380)
FINANCIAL EXPENSES	(157)	(160)
LOSS BEFORE TAX EXPENSES	(14,873)	(10,540)
TAX EXPENSES	45	4
NET LOSS	$ (14,918)	$ (10,544)
NET LOSS PER SHARE - basic and diluted	$ (2.03)	$ (6.97)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted	7,346,022	1,512,439

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Income Statement [Abstract]
Payment for complaint	$ 580

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands		Common Stock [Member]		Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019							$ 163,015	$ (157,632)	$ 5,383
Beginning balance, shares at Dec. 31, 2019		261,075		17,303	34,370
Net loss								(10,544)	(10,544)
Exercise of pre-funded warrants			[1]				18		18
Exercise of pre-funded warrants, shares		990,427
Settlement of restricted stock units in shares of common stock	[1]
Settlement of restricted stock units in shares of common stock, shares		11,000
Issuance of common shares, including at the market offering net of issuance costs			[1]				15,200		15,200
Issuance of common shares, including at the market offering net of issuance costs, shares		1,607,251
Exercise of Warrants F			[1]				1,418		1,418
Exercise of Warrants F, shares		191,107
Exercise of Unit Purchase Option			[1]				82		82
Exercise of Unit Purchase Option, shares		16,906
Conversion of Series C Convertible Preferred Stock to common shares			[1]			[1]				[1]
Conversion of series C convertible preferred stock to common stock, shares		24,812			(32,027)
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures			[1]				606		606
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares		181,744
Ending balance, value at Dec. 31, 2020							180,339	(168,176)	12,163
Ending balance, shares at Dec. 31, 2020		3,284,322		17,303	2,343
Net loss								(14,918)	(14,918)
Issuance of common shares, including at the market offering net of issuance costs		$ 1					25,241		25,242
Issuance of common shares, including at the market offering net of issuance costs, shares		3,133,775
Exercise of Warrants F			[2]				8,120		8,120
Exercise of Warrants F, shares		1,093,536
Exercise of Warrants G			[2]				1,349		$ 1,349
Exercise of Warrants G, shares		131,876
Conversion of Series B Convertible Preferred Stock to common shares	[2]
Conversion of series B convertible preferred stock to common stock, shares		207,528		(17,303)
Conversion of Series C Convertible Preferred Stock to common shares	[2]
Conversion of series C convertible preferred stock to common stock, shares		831			(625)
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures							1,576		1,576
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares		399,120
Round up of shares due to reverse stock split effectuated on April 26, 2021			[2]							[2]
Round up of shares due to reverse stock split effectuated on April 26, 2021, shares		45,268
Ending balance, value at Dec. 31, 2021		$ 1					$ 216,625	$ (183,094)	$ 33,532
Ending balance, shares at Dec. 31, 2021		8,296,256			1,718
[1]	Represents an amount less than $1
[2]	Represents an amount less than $1

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Payments of Stock Issuance Costs	$ 2,024	$ 1,110
Shares, restricted stock award, forfeited	20,822	3,717

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,918,000)	$ (10,544,000)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	161,000	151,000
Loss (gain) from sale of property, plant and equipment	(1,000)	14,000
Change in liability for employees rights upon retirement	142,000	181,000
Other financial expense (income)	8,000	(4,000)
Change in operating right of use asset and operating leasing liability	(14,000)	56,000
Noncash interest income on short-term deposits	(36,000)
Share-based compensation expenses	1,576,000	606,000
Gains on amounts funded in respect of employee rights upon retirement, net	(67,000)	(18,000)
Changes in operating asset and liability items:
Increase in prepaid expenses	(188,000)	(247,000)
Decrease (increase) in trade receivables	(748,000)	347,000
Decrease (increase) in other receivables	(19,000)	4,000
Decrease (increase) in inventory	272,000	(179,000)
Increase (decrease) in trade payables	657,000	(410,000)
Increase (decrease) in other payables	(35,000)	962,000
Net cash used in operating activities	(13,210,000)	(9,081,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(344,000)	(88,000)
Proceeds from sale of property, plant and equipment		22,000
Investment in short-term bank deposits	(24,000,000)
Withdrawal from short-term bank deposits	2,000,000
Amounts funded in respect of employee rights upon retirement, net	(113,000)	(121,000)
Net cash used in investing activities	(22,457,000)	(187,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares and warrants and exercise of Pre-Funded Warrants and unit purchase option, net of $2,024 and $1,110 issuance costs, respectively	35,034,000	16,395,000
Net cash provided by financing activities	35,034,000	16,395,000
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(8,000)	4,000
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(641,000)	7,131,000
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	12,645,000	5,514,000
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	12,004,000	12,645,000
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Acquisition of right-of-use assets by means of lease liabilities	91,000	619,000
Receivable for Shares		$ 323,000

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Issuance costs	$ 2,024	$ 1,110

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company’s coronary product combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). As a result of declining sales of the MGuard Prime EPS, we intend to phase out future sales of our MGuard Prime EPS in 2022. The Company markets its products through distributors in international markets, mainly in Europe. As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its products (primarily CGuard™ EPS) reach commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds. b. COVID-19 Pandemic The COVID-19 global pandemic has led governments and authorities around the globe to take various precautionary measures in order to limit the spread of COVID-19, including government-imposed quarantines, lockdowns, and other public health safety measures. We experienced a significant COVID-19 related impact on our financial condition and results of operations, primarily during the year ended December 31, 2020, which we primarily attribute to the postponement of CGuard EPS procedures (non-emergency procedures), as hospitals have shifted resources to patients affected by COVID-19. To the best of our knowledge, the European countries in which we operate reinstated non-emergency procedures. However, new COVID-19 variants, and potentially increasing infection rates make the current COVID-related environment highly volatile and uncertain and we anticipate that the continuation of the pandemic and related restrictions and safety measures will likely result in continued fluctuations in sales of our products and potentially enrollments in our studies as well as potential disruptions to our supply chain for the upcoming periods. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term. b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates. c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES e. Short-term bank deposits Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income. f. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”. g. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. h. Leases Operating leases are included in operating lease right-of-use (“ROU”) assets, Accounts payable and accruals - Other, and operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less. i. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method three years seven fifteen years seven years j. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES k. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. This occurs when products are shipped. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 10. The Company recognizes revenue net of value added tax (VAT). l. Research and development costs Research and development costs, including the costs of our US based clinical trial costs of approximately $ 2,037,000 m. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”). Employee equity awards are classified as equity awards and accounted for using the grant-date fair value method. The Company determines compensation expense associated with Restricted Stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. n. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. o. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES p. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $ 290,000 163,000 q. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period, including 11,696 61,515 2,840,179 2,166,218 r. Segment reporting The Company has one s. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The Company has no financial instruments measured carried at fair value in each reporting period. The fair value of the Company’s financial instruments approximates their carrying values. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES t. Issued accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not believe the adoption of this standard will have a material impact on its consolidated financial statements. In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832)”, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. However, it is not expected to have a material impact on the consolidated financial results of operations, financial position or cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 - PROPERTY, PLANT AND EQUIPMENT a. Composition of assets, grouped by major classifications, is as follows: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2021 2020 December 31, 2021 2020 ($ in thousands) Cost: Computer equipment $ 361 $ 289 Office furniture and equipment 157 95 Machinery and equipment 1,599 1,427 Leasehold improvements 243 211 Property plant and equipment, gross 2,360 2,022 Less - accumulated depreciation and amortization (1,728 ) (1,574 ) Net carrying amount $ 632 $ 448 b. Depreciation and amortization expenses totaled approximately $ 161,000 151,000

LIABILITY FOR EMPLOYEES RIGHT U

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT	NOTE 4 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, some of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33 The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses were approximately $ 265,000 276,000 Defined contribution plan expenses were approximately $ 415,000 339,000

LEASE AGREEMENTS

LEASE AGREEMENTS	12 Months Ended
	Dec. 31, 2021
Lease Agreements
LEASE AGREEMENTS	NOTE 5 – LEASE AGREEMENTS 1) The Company’s Israeli subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2022 with an option to extend the agreement for two additional years until December 31, 2024 under the terms stipulated in the agreement. The Option Period was taken in consideration when calculating the operating lease right of use assets and liabilities. In addition, the Company entered in June 2021 into another amendment to the lease agreement for a lease of additional space in the facility. This amendment was added to the ROU and the Lease liability. 2) The Company leases its motor vehicles under operating lease agreements. 3) Operating lease cost for the years ended December 31, 2021 and 2020 was $ 476,000 370,000 Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES December 31 December 31 2021 2020 ($ in thousands) ($ in thousands) Operating lease right-of-use assets 1,081 1,265 Current Operating lease liabilities (420 ) (400 ) Non-current operating lease liabilities (781 ) (999 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (437 ) (387 ) Weighted Average Remaining Lease Term 3 3.9 Weighted Average Discount Rate 8.38 % 8.38 % Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Amount ($ in thousands) 2022 433 2023 444 2024 465 Total lease payments 1,342 Less imputed interest (141 ) Total 1,201 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES a. Litigation: 1. In July 2019, a former distributor filed a suit seeking damages from the Company’s subsidiary for pre-paid goods subject to the voluntary field action (from April 2014) amounting to € 1,830,000 2.0 1,024,000 1.1 580,000 580,000 2. On July 28, 2020, we entered into a settlement agreement and release with the prior underwriter, under which it provided us a final, unconditional release from any further obligations arising out of or related to the engagement agreements, underwriting agreements and placement agency agreements which we had been party to with it and with respect to any services which it had provided to us. We, in turn, provided the prior underwriter a final, unconditional release from any further obligations arising out of or related to the prior agreements and services. As consideration for the final release provided to us, we paid to the prior underwriter $ 400,000 in cash and reduced, to $ 7.43 , the exercise price per share of warrants to purchase 18,277 shares of our common stock that had been issued by us to the prior underwriter in various offerings that took place between March 2018 and September 2019. That reduced exercise price represents the exercise price for the Series F Warrants that we issued in our June 2020 public offering. The warrants that were repriced had existing exercise prices per share ranging from $ 2,812.5 to $ 33.75 and a weighted average exercise price per share of $ 109.8 . All other terms of those warrants will remain unchanged. The related increase in expenses of $ 400,000 was recorded to “General and Administrative expense” within the Consolidated Statements of Operations. 3. In July 2020, a former senior employee of InspireMD GmbH filed a statement of claim at the Munich Labor Court, seeking confirmation of the court that the notice of termination is not effective. On November 10, 2020, we entered into a settlement agreement. As consideration for the final release, we paid the former senior employee 25,000 30,000 b. Distribution Agreement with Chinese Partner On February 3, 2021, the Company entered into a distribution agreement (the “Distribution Agreement”) with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’s products in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches. In addition, the agreement stipulates that if the Distributor fails to obtain the Regulatory Approvals by the time stipulated in the agreement due to the failure of the clinical trials, and this Agreement was terminated as a result of such failure to obtain Regulatory Approvals, InspireMD shall reimburse Distributor in an amount which is 50 1,000,000 50 See Note 7 for details regarding an investment transaction with one of the Chinese parties to the Distribution Agreement.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
EQUITY	NOTE 7 - EQUITY a. Share capital The Company’s shares that previously traded on the NYSE American were approved for listing on the Nasdaq Capital Market (“Nasdaq”) and such shares began trading on Nasdaq on May 21, 2021 under the symbol, “NSPR.” The Company’s warrants that previously traded on the NYSE American were approved for listing on Nasdaq, and such warrants began trading on Nasdaq on June 8, 2021. On April 19, 2021, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-fifteen reverse stock split of its common stock 0.0001 All related share and per share data have been retroactively applied to the financial statements and their related notes for all periods presented. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY Public Offering On June 5, 2020, the Company closed an underwritten public offering of (i) 509,053 0.0001 972,427 222,220 222,220 6.75 6.735 10.7 0.015 The Series F Warrants included in the Common Units and the Pre-Funded Units are immediately exercisable at a price of $ 7.425 During the year ended December 31, 2020, 191,107 191,107 1.4 Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series B Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B Convertible Preferred Stock and the Series C Preferred Stock was reduced to $ 6.75 ● An aggregate of 111,028 17,303 ● An aggregate of 18,886 26,558 for the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. The Company has also concluded that the series F warrants are classified as equity, since the warrants meet all criteria for equity classification. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY During the year ended December 31, 2020, the Company issued a total of 972,427 18,000 18,000 no On February 8, 2021, the Company closed an underwritten public offering (the “Offering”) of 1,935,484 0.0001 290,322 145,161 9.30 10.23 five years The Company granted the underwriter compensation warrants to purchase up to 111,290 10.23 five years The net proceeds to the Company from the Offering, after giving effect to the exercise of the underwriter’s over-allotment option, were approximately $ 18.9 On February 3, 2021, the Company entered into a Distribution Agreement with three China-based partners, See Note 6b. for details about the Distribution Agreement. In addition, and on the same day, the Company entered into an investment transaction with one of the Chinese parties to the Distribution Agreement, which included (i) a Securities Purchase Agreement (the “SPA”), pursuant to which investor agreed to invest $ 900,000 89,445 10.062 During the year ended December 31, 2021, Series F and Series G warrants to purchase shares of common stock were exercised by investors at an exercise price of $ 7.425 10.23 1,225,412 9,469,000 ATM Offering During the year ended December 31, 2020, the Company sold 861,163 4,447,000 During the year ended December 31, 2021, the Company sold 818,523 5,453,000 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series B Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B Convertible Preferred Stock and the Series C Preferred Stock was reduced to $ 4.815 ● an aggregate of 59,491 17,303 ● an aggregate of 893 2,343 On July 7, 2016, we issued 442,424 495.00 207,528 4.815 15% On March 14, 2017, we issued 1,069,822 96 3,114 4.815 During the year ended December 31, 2021, 625 831 1,718 2,284 During the year ended December 31, 2021, all the remaining 17,303 207,528 As of December 31, 2021, the Company has outstanding warrants to purchase an aggregate of 1,793,983 SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Weighted Series E Warrants 198,159 $ 27.000 Series F Warrants 433,878 $ 7.425 Series G Warrants 1,092,344 $ 10.230 Underwriter Warrants 18,277 $ 7.425 Other warrants 51,325 $ 225.000 and above Total Warrants 1,793,983 $ As of December 31, 2021, the Company has 155,000,000 0.0001 150,000,000 5,000,000 In the event of our liquidation, dissolution, or winding up, holders of Series C Convertible Preferred Stock are entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Preferred Stock if such shares had been converted to common stock immediately prior to such event. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY b. Share-Based Compensation 1) Pursuant to the current Section 102 of the Israeli Tax Ordinance, which came into effect on January 1, 2003, options may be granted through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e., Unapproved 102 Options). As a result of an election made by the Company under Section 102 of the Income Tax Ordinance, the Company will not be allowed to claim as an expense for tax purposes in Israel the amounts credited to the employee as capital gains to the grantees, although it will generally be entitled to do so in respect of the salary income component (if any) of such awards when the related tax is paid by the employee. 2) During the years ended December 31, 2021 and 2020, the Company granted stock options to the CEO, employees, consultants and directors to purchase a total of 225,225 and 92,007 , respectively, shares of the Company’s common stock. The options have exercise prices ranging from $ 3.89 -$ 10.05 and $ 4.95 -$ 16.50 per share, respectively, which were the fair market value of the company’s common stock on the date of each respective grant. The fair value of the above options, using the Black-Scholes pricing models, was approximately $ 1,026,000 and $ 509,000 , respectively. The options are subject to a three -year vesting period with one-third of such awards vesting each year. 3) During the years ended December 31, 2021 and 2020, the Company granted to the employees and directors 419,943 185,461 1,781,981 1,051,604 three 4) During the years ended December 31, 2021 and 2020, the Company granted to the CEO 146,567 90,511 603,856 658,981 three INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY 5) The following table summarizes information about stock options granted to employees: SCHEDULE OF STOCK OPTIONS GRANTED Year ended December 31 2021 2020 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 91,692 6.20 - $ - Granted 205,223 4.90 92,007 6.20 Forfeited (7,507 ) 5.69 (315 ) 5.85 Outstanding-end of period 289,408 $ 5.29 91,692 $ 6.20 Exercisable at the end of the period 28,360 6.26 - - 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2021 2020 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period - - - - Granted 20,002 6.90 - - Forfeited - - - - Exercised - - - - Outstanding - end of period 20,002 6.90 - - Exercisable at the end of the period - - - - 7) The following table summarizes information about restricted stock granted to employees: SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES Year ended December 31 2021 2020 Number of restricted stock Outstanding - beginning of period 185,725 4,642 Reverse Split Adjustments 59 - Granted 419,943 185,461 Forfeited (20,822 ) (3,717 ) Vested (57,237 ) (661 ) Outstanding - end of period 527,668 185,725 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY 8) The following table summarizes information about Restricted Stock Units granted to employees: SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES Year ended December 31 2021 2020 Number of restricted stock units Outstanding - beginning of period 90,511 11,000 Granted 146,567 90,511 Forfeited - - Vested - (11,000 ) Outstanding - end of period 237,078 90,511 9) The following table provides additional information about all options outstanding and exercisable: SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE Outstanding as of December 31, 2021 Exercise price Options outstanding Weighted average remaining contractual life (years) Options exercisable $ 3.89 4.12 146,539 9.81 - $ 4.95 10.05 158,819 8.99 27,009 $ 16.50 4,052 8.01 1,351 309,410 9 .37 28,361 The weighted average of the remaining contractual life of total vested and exercisable options as of December 31, 2021 was 8.65 The aggregate intrinsic value of the total exercisable options as of December 31, 2021 was approximately $ 0.4 The weighted average fair value of options granted was $ 4.56 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 7 – EQUITY 10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2021: SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES Year ended December 31 2021 2020 Number of restricted stock Expected life 5.5 6.5 5.5 6.5 Risk-free interest rates 0.59 1.40 % 0.32 0.42 % Volatility 129.11 136.78 % 124.53 136.66 % Dividend yield - - The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life). The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from its historical data. 11) As of December 31, 2021, the total unrecognized compensation cost on employee and non-employee stock options, restricted stock and restricted stock units, related to unvested stock-based compensation, amounted to approximately $ 3.4 1.01 12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE Year ended December 31 2021 2020 ($ in thousands) Cost of revenues $ 49 $ 22 Research and development 64 29 Sales and marketing 182 32 General and administrative 1,281 523 $ 1,576 $ 606 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

RELATED PARTIES TRANSACTIONS

RELATED PARTIES TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	NOTE 8 – RELATED PARTIES TRANSACTIONS On May 10, 2021, the board of directors of the Company appointed a new member. During the twelve months ended December 31, 2021, a consulting company whose founder and CEO is our new board member provided certain marketing services in the amount of $ 33,775

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
TAXES ON INCOME	NOTE 9 - TAXES ON INCOME a. Tax laws applicable to the Company and its subsidiaries Taxation in the United States InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2021 is 21 Taxation in Israel InspiredMD, Ltd is taxed under Israeli tax laws. Accordingly, the applicable corporate tax rate in 2021 is 23 Taxation in Germany InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825 17.15 b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”): InspireMD Ltd. has been granted a “Beneficiary Enterprises” status under the Investment Law including Amendment No. 60 thereof, which became effective in April 2005. The tax benefits derived from any such Beneficiary Enterprise relate only to taxable profits attributable to the specific program of investment to which the status was granted. The main benefit, to which InspireMD Ltd. is entitled, conditional upon the fulfilling of certain conditions stipulated by the above law, is a two-year exemption and five to eight years of a reduced tax rate of 10 23 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 - TAXES ON INCOME In the event of a distribution of tax-exempt income attributable to “Beneficiary Enterprises” as a cash dividend, the Company will be required to pay tax at a rate of 10% to 23% on the amount distributed, subject to certain conditions. In addition, dividends originating from income attributable to the “Beneficiary Enterprises” will be subject to a 20 Should InspireMD Ltd. derive income from sources other than the “Beneficiary Enterprises” during the period of benefits, such income shall be taxable at the regular corporate tax rate. 1) Conditions for entitlement to the benefits The entitlement to the above benefits is conditional upon InspireMD Ltd. fulfilling the conditions stipulated by the law, regulations published thereunder and the instruments of approval for the specific investments in approved assets. In the event of failure to comply with these conditions, the benefits may be cancelled, and InspireMD Ltd. may be required to refund the amount of the benefits, in whole or in part, with the addition of interest and linkage. The Company opted not to apply for Preferred Enterprise status (as defined in the Amendment of the Law for the Encouragement of Capital Investments, 1959). c. Carry forward tax losses As of December 31, 2021, the Company had a net carry forward tax loss of approximately $ 47 35 expires until 2037 12 80 Under the U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income. In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue to have a two-year carryback and twenty-year carryforward period. Further to COVID-19 CARES act of the U.S. Treasury, the business tax provision temporarily removes the current law taxable income 80 five years As of December 31, 2021, InspireMD Ltd., an Israeli subsidiary, had a net carry forward tax loss of approximately $ 109 d. Loss before income taxes The components of loss before income taxes are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES Year ended December 31 2021 2020 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (4,452 ) $ (3,897 ) Subsidiaries (10,421 ) (6,643 ) $ (14,873 ) $ (10,540 ) INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 - TAXES ON INCOME e. Current taxes on income The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits. The changes in the valuation allowance for the year ended December 31, 2021 and 2020 were as follows: SCHEDULE OF CHANGES IN VALUATION ALLOWANCE Year ended December 31 2021 2020 ($ in thousands) Balance at the beginning of the year $ 35,145 $ 31,181 Changes during the year: Losses during the year (including foreign exchange rate effect) 4,067 3,964 Balance at the end of the year $ 39,212 $ 35,145 f. Accounting for Uncertain Tax position Following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2021 and 2020 were as follows: SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS Year ended December 31, 2021 2020 ($ in thousands) Balance at beginning of period $ 52 $ 44 Increase in uncertain tax positions because of tax positions taken during the year 37 8 Balance at end of period $ 89 $ 52 A summary of open tax years by major jurisdiction is presented below: SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION Jurisdiction Years U.S. 2018 2021 Israel 2016 2021 Germany 2018 2021 United Kingdom 2014 2015 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 9 - TAXES ON INCOME g. Deferred income tax: SCHEDULE OF DEFERRED INCOME TAX 2021 2020 December 31, 2021 2020 ($ in thousands) Long-term: Allowance for bonus - 2 Provision for vacation and recreation pay 53 63 R&D expenses 1,000 578 Operating lease right of use assets (248 ) (291 ) Operating lease liabilities 276 322 Share-based compensation 2,849 2,669 Carry forward tax losses 35,248 31,759 Accrued severance pay, net 34 43 Deferred tax assets noncurrent 39,212 35,145 Less-valuation allowance (39,212 ) (35,145 ) Deferred tax assets - -

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 10 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Balance sheets: Inventory: SCHEDULE OF INVENTORIES 2021 2020 December 31, 2021 2020 ($ in thousands) Finished goods $ 92 $ 350 Work in process 436 376 Raw materials and supplies 615 689 Total inventory $ 1,143 $ 1,415 INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 10 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION a. Accounts payable and accruals-other: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER 2021 2020 December 31, 2021 2020 ($ in thousands) Employees and employee institutions $ 1,510 $ 1,236 Accrued vacation and recreation pay 233 278 Accrued expenses 1,136 886 Accrual for settlement payment (see note 6) - 580 Current Operating lease liabilities 420 400 Other 155 89 Accounts Payable and Accruals - Other $ 3,454 $ 3,469

DISAGGREGATED REVENUE AND ENTIT

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	NOTE 11 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Year ended December 31, 2021 2020 ($ in thousands) Germany $ 948 $ 708 Italy 981 596 Other (2020 - net of settlement payment of $ 580 2,566 1,181 $ 4,495 $ 2,485 By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Year ended December 31, 2021 2020 ($ in thousands) CGuard™ EPS $ 4,309 $ 2,764 MGuard Prime™ EPS (2020 - net of settlement payment of $ 580 186 (279 ) $ 4,495 $ 2,485 By principal customers (2020 - before of settlement payment of $ 580 SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Year ended December 31, 2021 2020 Customer A 20 % 21 % Customer B 13 % 11 % All tangible long lived assets are located in Israel.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 - SUBSEQUENT EVENTS In February 2022, Russia launched a military invasion into Ukraine. The Company derived approximately 8.2% of total sales in Russia in 2021. The Company may have impact on future sales and collection but currently the Company is still unable to estimate any specific impact to its business, financial condition or results of operations.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations and assessing the likelihood of exercise of options to extend the lease term.
Functional currency	b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.
Principles of consolidation	c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and cash equivalents	d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Short-term bank deposits	e. Short-term bank deposits Bank deposits with original maturities of more than three months but less than one year are presented as part of short-term bank deposits. Deposits are presented at their cost which approximates market values including accrued interest. Interest on deposits is recorded as financial income.
Concentration of credit risk and allowance for doubtful accounts	f. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”.
Inventory	g. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value.
Leases	h. Leases Operating leases are included in operating lease right-of-use (“ROU”) assets, Accounts payable and accruals - Other, and operating lease liabilities. ROU assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of the incremental borrowing rate requires management judgment based on information available at lease commencement. The lease terms may include periods covered by options to extend the lease when it is reasonably certain that the Company will exercise such options, and periods covered by options to terminate the lease when it is reasonably certain that the Company will not exercise such options. Operating lease cost is recognized on a straight-line basis over the lease term. Lease agreements that include lease and non-lease components are accounted for as a single lease component. The Company elected the short-term lease recognition exemption for leases with a lease term of 12 months or less.
Property, plant and equipment	i. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method three years seven fifteen years seven years
Impairment in value of long-lived assets	j. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Revenue recognition	k. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. This occurs when products are shipped. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 10. The Company recognizes revenue net of value added tax (VAT).
Research and development costs	l. Research and development costs Research and development costs, including the costs of our US based clinical trial costs of approximately $ 2,037,000
Share-based compensation	m. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”). Employee equity awards are classified as equity awards and accounted for using the grant-date fair value method. The Company determines compensation expense associated with Restricted Stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach.
Uncertain tax positions	n. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Deferred income taxes	o. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Advertising	p. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $ 290,000 163,000
Net loss per share	q. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period, including 11,696 61,515 2,840,179 2,166,218
Segment reporting	r. Segment reporting The Company has one
Fair value measurement	s. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The Company has no financial instruments measured carried at fair value in each reporting period. The fair value of the Company’s financial instruments approximates their carrying values. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
Issued accounting pronouncements effective in future periods	t. Issued accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not believe the adoption of this standard will have a material impact on its consolidated financial statements. In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832)”, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. However, it is not expected to have a material impact on the consolidated financial results of operations, financial position or cash flows. INSPIREMD, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2021 2020 December 31, 2021 2020 ($ in thousands) Cost: Computer equipment $ 361 $ 289 Office furniture and equipment 157 95 Machinery and equipment 1,599 1,427 Leasehold improvements 243 211 Property plant and equipment, gross 2,360 2,022 Less - accumulated depreciation and amortization (1,728 ) (1,574 ) Net carrying amount $ 632 $ 448

LEASE AGREEMENTS (Tables)

LEASE AGREEMENTS (Tables)	12 Months Ended
	Dec. 31, 2021
Lease Agreements
SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES	Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES December 31 December 31 2021 2020 ($ in thousands) ($ in thousands) Operating lease right-of-use assets 1,081 1,265 Current Operating lease liabilities (420 ) (400 ) Non-current operating lease liabilities (781 ) (999 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (437 ) (387 ) Weighted Average Remaining Lease Term 3 3.9 Weighted Average Discount Rate 8.38 % 8.38 %
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES Amount ($ in thousands) 2022 433 2023 444 2024 465 Total lease payments 1,342 Less imputed interest (141 ) Total 1,201

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK	SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Weighted Series E Warrants 198,159 $ 27.000 Series F Warrants 433,878 $ 7.425 Series G Warrants 1,092,344 $ 10.230 Underwriter Warrants 18,277 $ 7.425 Other warrants 51,325 $ 225.000 and above Total Warrants 1,793,983 $
SCHEDULE OF STOCK OPTIONS GRANTED	5) The following table summarizes information about stock options granted to employees: SCHEDULE OF STOCK OPTIONS GRANTED Year ended December 31 2021 2020 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 91,692 6.20 - $ - Granted 205,223 4.90 92,007 6.20 Forfeited (7,507 ) 5.69 (315 ) 5.85 Outstanding-end of period 289,408 $ 5.29 91,692 $ 6.20 Exercisable at the end of the period 28,360 6.26 - - 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2021 2020 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period - - - - Granted 20,002 6.90 - - Forfeited - - - - Exercised - - - - Outstanding - end of period 20,002 6.90 - - Exercisable at the end of the period - - - -
SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES	7) The following table summarizes information about restricted stock granted to employees: SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES Year ended December 31 2021 2020 Number of restricted stock Outstanding - beginning of period 185,725 4,642 Reverse Split Adjustments 59 - Granted 419,943 185,461 Forfeited (20,822 ) (3,717 ) Vested (57,237 ) (661 ) Outstanding - end of period 527,668 185,725
SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES	8) The following table summarizes information about Restricted Stock Units granted to employees: SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES Year ended December 31 2021 2020 Number of restricted stock units Outstanding - beginning of period 90,511 11,000 Granted 146,567 90,511 Forfeited - - Vested - (11,000 ) Outstanding - end of period 237,078 90,511
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE	9) The following table provides additional information about all options outstanding and exercisable: SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE Outstanding as of December 31, 2021 Exercise price Options outstanding Weighted average remaining contractual life (years) Options exercisable $ 3.89 4.12 146,539 9.81 - $ 4.95 10.05 158,819 8.99 27,009 $ 16.50 4,052 8.01 1,351 309,410 9 .37 28,361
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES	SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES Year ended December 31 2021 2020 Number of restricted stock Expected life 5.5 6.5 5.5 6.5 Risk-free interest rates 0.59 1.40 % 0.32 0.42 % Volatility 129.11 136.78 % 124.53 136.66 % Dividend yield - -
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE	SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE Year ended December 31 2021 2020 ($ in thousands) Cost of revenues $ 49 $ 22 Research and development 64 29 Sales and marketing 182 32 General and administrative 1,281 523 $ 1,576 $ 606

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES	The components of loss before income taxes are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES Year ended December 31 2021 2020 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (4,452 ) $ (3,897 ) Subsidiaries (10,421 ) (6,643 ) $ (14,873 ) $ (10,540 )
SCHEDULE OF CHANGES IN VALUATION ALLOWANCE	The changes in the valuation allowance for the year ended December 31, 2021 and 2020 were as follows: SCHEDULE OF CHANGES IN VALUATION ALLOWANCE Year ended December 31 2021 2020 ($ in thousands) Balance at the beginning of the year $ 35,145 $ 31,181 Changes during the year: Losses during the year (including foreign exchange rate effect) 4,067 3,964 Balance at the end of the year $ 39,212 $ 35,145
SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS	Following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2021 and 2020 were as follows: SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS Year ended December 31, 2021 2020 ($ in thousands) Balance at beginning of period $ 52 $ 44 Increase in uncertain tax positions because of tax positions taken during the year 37 8 Balance at end of period $ 89 $ 52
SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION	A summary of open tax years by major jurisdiction is presented below: SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION Jurisdiction Years U.S. 2018 2021 Israel 2016 2021 Germany 2018 2021 United Kingdom 2014 2015
SCHEDULE OF DEFERRED INCOME TAX	g. Deferred income tax: SCHEDULE OF DEFERRED INCOME TAX 2021 2020 December 31, 2021 2020 ($ in thousands) Long-term: Allowance for bonus - 2 Provision for vacation and recreation pay 53 63 R&D expenses 1,000 578 Operating lease right of use assets (248 ) (291 ) Operating lease liabilities 276 322 Share-based compensation 2,849 2,669 Carry forward tax losses 35,248 31,759 Accrued severance pay, net 34 43 Deferred tax assets noncurrent 39,212 35,145 Less-valuation allowance (39,212 ) (35,145 ) Deferred tax assets - -

SUPPLEMENTARY FINANCIAL STATE_2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF INVENTORIES	Inventory: SCHEDULE OF INVENTORIES 2021 2020 December 31, 2021 2020 ($ in thousands) Finished goods $ 92 $ 350 Work in process 436 376 Raw materials and supplies 615 689 Total inventory $ 1,143 $ 1,415
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER	a. Accounts payable and accruals-other: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER 2021 2020 December 31, 2021 2020 ($ in thousands) Employees and employee institutions $ 1,510 $ 1,236 Accrued vacation and recreation pay 233 278 Accrued expenses 1,136 886 Accrual for settlement payment (see note 6) - 580 Current Operating lease liabilities 420 400 Other 155 89 Accounts Payable and Accruals - Other $ 3,454 $ 3,469

DISAGGREGATED REVENUE AND ENT_2

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Year ended December 31, 2021 2020 ($ in thousands) Germany $ 948 $ 708 Italy 981 596 Other (2020 - net of settlement payment of $ 580 2,566 1,181 $ 4,495 $ 2,485
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT	By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Year ended December 31, 2021 2020 ($ in thousands) CGuard™ EPS $ 4,309 $ 2,764 MGuard Prime™ EPS (2020 - net of settlement payment of $ 580 186 (279 ) $ 4,495 $ 2,485
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS	By principal customers (2020 - before of settlement payment of $ 580 SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Year ended December 31, 2021 2020 Customer A 20 % 21 % Customer B 13 % 11 %

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)segmentshares	Dec. 31, 2020USD ($)shares
Property, Plant and Equipment [Line Items]
Description of methodology used for computing depreciation	straight-line method
Research and development costs | $	$ 2,037,000
Description of uncertain tax benefits	the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising expense | $	$ 290,000	$ 163,000
Weighted average shares common stock issuable	7,346,022	1,512,439
Number of operating segment | segment	1
Number of reportable segment | segment	1
Series B Convertible Preferred Stock One [Member]
Property, Plant and Equipment [Line Items]
Weighted average shares common stock issuable	11,696	61,515
Series C Convertible Preferred Stock One [Member]
Property, Plant and Equipment [Line Items]
Weighted average shares common stock issuable	2,840,179	2,166,218
Computers and Other Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Office Furniture and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Office Furniture and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 2,360	$ 2,022
Less - accumulated depreciation and amortization	(1,728)	(1,574)
Net carrying amount	632	448
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	361	289
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	157	95
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	1,599	1,427
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 243	$ 211

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization expenses	$ 161,000	$ 151,000

LIABILITY FOR EMPLOYEES RIGHT_2

LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Percentage of monthly deposits on salary	8.33%
Severance expenses	$ 265,000	$ 276,000
Defined contribution plan expense	$ 415,000	$ 339,000

SCHEDULE OF SUPPLEMENTAL INFORM

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lease Agreements
Operating lease right-of-use assets	$ 1,081	$ 1,265
Current Operating lease liabilities	(420)	(400)
Non-current operating lease liabilities	(781)	(999)
Operating cash flows from operating leases (cash paid in thousands)	$ (437)	$ (387)
Weighted Average Remaining Lease Term	3 years	3 years 10 months 24 days
Weighted Average Discount Rate	8.38%	8.38%

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) $ in Thousands	Dec. 31, 2021USD ($)
Lease Agreements
2022	$ 433
2023	444
2024	465
Total lease payments	1,342
Less imputed interest	(141)
Total	$ 1,201

LEASE AGREEMENTS (Details Narra

LEASE AGREEMENTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lease Agreements
Operating lease expense	$ 476,000	$ 370,000

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)	Feb. 03, 2021USD ($)	Jul. 28, 2020USD ($)$ / sharesshares	Jan. 31, 2021USD ($)	Jul. 31, 2020USD ($)	Jul. 31, 2020EUR (€)	Jul. 31, 2019USD ($)	Jul. 31, 2019EUR (€)	Dec. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)
Loss Contingencies [Line Items]
Payment for complaint									$ 580,000
Repayments of Related Party Debt		$ 400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 7.43
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		18,277						1,793,983
Weighted average exercise price | $ / shares		$ 109.8
Increase in provision for general and administrative expenses		$ 400,000
Selling and marketing expense								$ 2,907,000	2,103,000
Distribution cost rate	50.00%							50.00%
Distribution reimbursement	$ 1,000,000
Minimum [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 2,812.5
Maximum [Member]
Loss Contingencies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 33.75
Settlement Agreement [Member] | Former Senior Employee [Member]
Loss Contingencies [Line Items]
Selling and marketing expense				$ 30,000	€ 25,000
Former Distributor [Member]
Loss Contingencies [Line Items]
Law suit seeking damages						$ 2,000,000	€ 1,830,000
Former Distributor [Member] | Mediation Agreement [Member]
Loss Contingencies [Line Items]
Payment for complaint			$ 580,000						$ 580,000
Former Distributor [Member] | Alternatively [Member]
Loss Contingencies [Line Items]
Law suit seeking damages						$ 1,100,000	€ 1,024,000

SCHEDULE OF ISSUANCE OF WARRANT

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details) - $ / shares	Dec. 31, 2021	Jul. 28, 2020
Class of Stock [Line Items]
Total Warrants	1,793,983	18,277
Weighted average exercise price		$ 7.43
Series E Warrants [Member]
Class of Stock [Line Items]
Total Warrants	198,159
Weighted average exercise price	$ 27
Series F Warrants [Member]
Class of Stock [Line Items]
Total Warrants	433,878
Weighted average exercise price	$ 7.425
Series G Warrants [Member]
Class of Stock [Line Items]
Total Warrants	1,092,344
Weighted average exercise price	$ 10.230
Underwriter Warrants [Member]
Class of Stock [Line Items]
Total Warrants	18,277
Weighted average exercise price	$ 7.425
Other Warrants [Member]
Class of Stock [Line Items]
Total Warrants	51,325
Weighted average exercise price, description	225.000 and above

SCHEDULE OF STOCK OPTIONS GRANT

SCHEDULE OF STOCK OPTIONS GRANTED (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of options Outstanding - beginning of period	91,692
Weighted average exercise price Outstanding - beginning of period	$ 6.20
Number of options Outstanding, Granted	205,223	92,007
Weighted average exercise price, Granted	$ 4.90	$ 6.20
Number of options Outstanding, Forfeited	(7,507)	(315)
Weighted average exercise price, Forfeited	$ 5.69	$ 5.85
Number of options Outstanding, Outstanding -end of period	289,408	91,692
Weighted average exercise price, Outstanding -end of period	$ 5.29	$ 6.20
Number of options Outstanding, Exercisable at the end of the period	28,360
Weighted average exercise price, Exercisable at the end of the period	$ 6.26
Non-Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of options Outstanding - beginning of period
Weighted average exercise price Outstanding - beginning of period
Number of options Outstanding, Granted	20,002
Weighted average exercise price, Granted	$ 6.90
Number of options Outstanding, Forfeited
Weighted average exercise price, Forfeited
Number of options Outstanding, Outstanding -end of period	20,002
Weighted average exercise price, Outstanding -end of period	$ 6.90
Number of options Outstanding, Exercisable at the end of the period
Weighted average exercise price, Exercisable at the end of the period
Number of options Outstanding, Exercised
Weighted average exercise price, Exercised

SCHEDULE OF RESTRICTED STOCK GR

SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES (Details) - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Granted	419,943	185,461
Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Number of restricted stock, Outstanding - beginning of period	185,725	4,642
Number of restricted stock, Reverse Split Adjustments	59
Number of restricted stock, Granted	419,943	185,461
Number of restricted stock, Forfeited	(20,822)	(3,717)
Number of restricted stock, Vested	(57,237)	(661)
Number of restricted stock, Outstanding - end of period	527,668	185,725

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES (Details) - Restricted Stock Units (RSUs) [Member] - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock, Granted	146,567	90,511
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock, Outstanding - beginning of period	90,511	11,000
Number of restricted stock, Granted	146,567	90,511
Number of restricted stock, Forfeited
Number of restricted stock, Vested		(11,000)
Number of restricted stock, Outstanding - end of period	237,078	90,511

SCHEDULE OF ADDITIONAL INFORMAT

SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 309,410
Weighted average remaining contractual life (years)	4 months 13 days
Options exercisable	28,361
Exercise Price One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 3.89
Exercise price | $ / shares	$ 4.12
Exercise Price [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	146,539
Weighted average remaining contractual life (years)	9 years 9 months 21 days
Options exercisable
Exercise Price Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price lower range | $ / shares	$ 4.95
Exercise price | $ / shares	$ 10.05
Options outstanding	158,819
Weighted average remaining contractual life (years)	8 years 11 months 26 days
Options exercisable	27,009
Exercise Price Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 16.50
Options outstanding	4,052
Weighted average remaining contractual life (years)	8 years 3 days
Options exercisable	1,351

SCHEDULE OF FAIR VALUE OF OPTIO

SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Risk-free interest rate, minimum	0.59%	0.32%
Risk-free interest rate, maximum	1.40%	0.42%
Volatility, minimum	129.11%	124.53%
Volatility, maximum	136.78%	136.66%
Dividend yield
Minimum [Member]
Expected life	5 years 6 months	5 years 6 months
Maximum [Member]
Expected life	6 years 6 months	6 years 6 months

SCHEDULE OF ALLOCATION OF TOTAL

SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Total share-based compensation expense	$ 1,576	$ 606
Cost of Sales [Member]
Total share-based compensation expense	49	22
Research and Development Expense [Member]
Total share-based compensation expense	64	29
Selling and Marketing Expense [Member]
Total share-based compensation expense	182	32
General and Administrative Expense [Member]
Total share-based compensation expense	$ 1,281	$ 523

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	Apr. 19, 2021	Feb. 08, 2021	Feb. 03, 2021	Jun. 05, 2020	Mar. 14, 2017	Jul. 07, 2016	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2020	Dec. 14, 2020	Jul. 28, 2020	Jun. 02, 2020	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Reverse stock split	one-for-fifteen reverse stock split of its common stock
Common stock, par value	$ 0.0001						$ 0.0001	$ 0.0001	$ 0.0001
Warrants exercise price											$ 7.43
Outstanding pre-funded warrants are exercisable into shares of common stock								0	0
Warrants to purchase common stock							1,793,983				18,277
Capital stock shares authorized							155,000,000
Capital stock par value							$ 0.0001
Common stock shares authorized							150,000,000	150,000,000	150,000,000
Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price											$ 2,812.5
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price											$ 33.75
Share-based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures							225,225	92,007
Fair value of stock options							$ 1,026,000	$ 509,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							3 years
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 3.89	$ 4.95
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 10.05	$ 16.50
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock granted							419,943	185,461
Fair value of restricted shares							$ 1,781,981	$ 1,051,604
Stock vesting period							3 years
Weighted average of the remaining contractual life of vested and exercisable options							8 years 7 months 24 days
Aggregate intrinsic value of exercisable options							$ 400,000
Weighted average fair value of options granted							4.56
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Stock granted							146,567	90,511
Stock vesting period							3 years
Fair value of restricted stock units							$ 603,856	$ 658,981
Employee and Non-employee Stock Options [Member]
Subsidiary, Sale of Stock [Line Items]
Unvested stock-based compensation							$ 3,400,000
Unvested stock-based compensation weighted-average period for recognition							1 year 3 days
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock convertible, shares							17,303
Converted preferred stock							207,528
Preferred stock outstanding							0	17,303	17,303
Preferred stock shares authorized							500,000	500,000	500,000
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock outstanding							1,718	2,343	2,343
Preferred stock shares authorized							1,172,000	1,172,000	1,172,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							3,133,775	1,607,251
Shares outstanding							8,296,256	3,284,322	3,284,322				261,075
Preferred Stock Blank Check [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized							5,000,000
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering			89,445
Share price			$ 10.062
Proceeds from sale of stock			$ 900,000
Underwritten Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, par value		$ 0.0001		$ 0.0001
Number of issuance of public offering		1,935,484		509,053
Share price		$ 9.30		$ 6.75
Proceeds from exercise of warrants				$ 10,700,000
Warrants exercise price				$ 0.015
Net proceeds from issuance of stock		$ 18,900,000
Underwritten Public Offering [Member] | Series B Convertible Preferred Stock and Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Share price				$ 6.75
Underwritten Public Offering [Member] | Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Additional shares of common stock												111,028
Shares outstanding												17,303
Underwritten Public Offering [Member] | Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Additional shares of common stock												18,886
Shares outstanding												26,558
Underwritten Public Offering [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							1,225,412
Over allotment shares		290,322		222,220
Conversion of convertible securities								191,107
Proceeds from sale of stock							$ 9,469,000
Underwritten Public Offering [Member] | Series F Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Over allotment shares				222,220
Warrants exercise price				$ 7.425			$ 7.425
Conversion of convertible securities								191,107
Proceeds from exercise of warrants								$ 1,400,000
Underwritten Public Offering [Member] | Series G Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Over allotment shares		145,161
Share price		$ 10.23
Warrants exercise price							$ 10.23
Warrants and Rights Outstanding, Term		5 years
Underwritten Public Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price		$ 10.23
Warrants and Rights Outstanding, Term		5 years
Warrants to purchase common stock		111,290
Underwritten Public Offering [Member] | Pre-Funded Units [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering				972,427
Share price				$ 6.735
Underwritten Public Offering [Member] | Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued for exercise of warrants								972,427	18,000
At The Market Offering [Member] | Series B Convertible Preferred Stock and Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Share price				$ 4.815
At The Market Offering [Member] | Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering						442,424
Share price						$ 495
Additional shares of common stock										59,491
Shares outstanding										17,303
Preferred stock convertible, shares						207,528
Conversion price per share						$ 4.815
Dividend rate						15.00%
At The Market Offering [Member] | Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering					1,069,822
Share price					$ 96
Additional shares of common stock										893
Shares outstanding										2,343
Preferred stock convertible, shares					3,114
Conversion price per share					$ 4.815
Converted preferred stock							2,284
Preferred stock outstanding							1,718
At The Market Offering [Member] | Series C Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock convertible, shares							625
At The Market Offering [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering							818,523	861,163
Net proceeds from issuance of stock							$ 5,453,000	$ 4,447,000
Converted preferred stock							831
At The Market Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding							1,793,983

RELATED PARTIES TRANSACTIONS (D

RELATED PARTIES TRANSACTIONS (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)
New Director [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Marketing services expense	$ 33,775

SCHEDULE OF COMPONENTS OF LOSS

SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Loss before taxes on income	$ (14,873)	$ (10,540)
Parent Company [Member]
Loss before taxes on income	(4,452)	(3,897)
Subsidiaries [Member]
Loss before taxes on income	$ (10,421)	$ (6,643)

SCHEDULE OF CHANGES IN VALUATIO

SCHEDULE OF CHANGES IN VALUATION ALLOWANCE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 35,145	$ 31,181
Changes during the year: Losses during the year (including foreign exchange rate effect)	4,067	3,964
Balance at the end of the year	$ 39,212	$ 35,145

SCHEDULE OF RECONCILIATION OF U

SCHEDULE OF RECONCILIATION OF UNCERTAIN TAX POSITIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Uncertain tax positions balance at beginning of period	$ 52	$ 44
Increase in uncertain tax positions because of tax positions taken during the year	37	8
Uncertain tax positions balance at end of period	$ 89	$ 52

SCHEDULE OF OPEN TAX YEARS BY M

SCHEDULE OF OPEN TAX YEARS BY MAJOR JURISDICTION (Details)	12 Months Ended
	Dec. 31, 2021
UNITED STATES | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2018
UNITED STATES | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2021
ISRAEL | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2016
ISRAEL | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2021
GERMANY | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2018
GERMANY | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2021
UNITED KINGDOM | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2014
UNITED KINGDOM | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2015

SCHEDULE OF DEFERRED INCOME TAX

SCHEDULE OF DEFERRED INCOME TAX (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Allowance for bonus		$ 2
Provision for vacation and recreation pay	53	63
R&D expenses	1,000	578
Operating lease right of use assets	(248)	(291)
Operating lease liabilities	276	322
Share-based compensation	2,849	2,669
Carry forward tax losses	35,248	31,759
Accrued severance pay, net	34	43
Deferred tax assets noncurrent	39,212	35,145
Less-valuation allowance	(39,212)	(35,145)	$ (31,181)
Deferred tax assets

TAXES ON INCOME (Details Narrat

TAXES ON INCOME (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate	21.00%
Tax rate on income of beneficiary enterprises	20.00%
Net carry forward tax loss	$ 47				$ 35
Net loss carryforwards percentage	80.00%	80.00%	80.00%	80.00%
Operating loss carryforwards expiration period		5 years
Arising Before January One Two Thousand And Eighteen [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration description		expires until 2037
Limited [Member]
Operating Loss Carryforwards [Line Items]
Net carry forward tax loss	$ 12
Israel Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate	23.00%
Revised tax rate on income of preferred enterprises	10.00%
Tax rate on income of beneficiary enterprises	23.00%
Net carry forward tax loss	$ 109
Germany [Member]
Operating Loss Carryforwards [Line Items]
Federal corporate tax rate	15.825%
Corporate trade tax rate	17.15%

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 92	$ 350
Work in process	436	376
Raw materials and supplies	615	689
Total inventory	$ 1,143	$ 1,415

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Employees and employee institutions	$ 1,510	$ 1,236
Accrued vacation and recreation pay	233	278
Accrued expenses	1,136	886
Accrual for settlement payment (see note 6)		580
Current Operating lease liabilities	420	400
Other	155	89
Accounts Payable and Accruals - Other	$ 3,454	$ 3,469

SCHEDULE OF REVENUES ATTRIBUTED

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 4,495	$ 2,485
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	948	708
ITALY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	981	596
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 2,566	$ 1,181

SCHEDULE OF REVENUES ATTRIBUT_2

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Net of settlement	$ 580
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net of settlement	$ 580

SCHEDULE OF REVENUES ATTRIBUT_3

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from External Customer [Line Items]
Revenue	$ 4,495	$ 2,485
CGuard EPS [Member]
Revenue from External Customer [Line Items]
Revenue	4,309	2,764
MGuard Prime EPS [Member]
Revenue from External Customer [Line Items]
Revenue	$ 186	$ (279)

SCHEDULE OF REVENUES ATTRIBUT_4

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Segment Reporting [Abstract]
Net of settlement	$ 580

SCHEDULE OF REVENUES ATTRIBUT_5

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) - Sales [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Customer A [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	20.00%	21.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	13.00%	11.00%